Arcus Biosciences Inc (RCUS)
15.50
+0.27
(+1.77%)
USD |
NYSE |
May 01, 16:00
15.50
0.00 (0.00%)
After-Hours: 20:00
Arcus Biosciences Research and Development Expense (Quarterly): 93.00M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 93.00M |
| September 30, 2023 | 82.00M |
| June 30, 2023 | 84.00M |
| March 31, 2023 | 81.00M |
| December 31, 2022 | 80.00M |
| September 30, 2022 | 77.00M |
| June 30, 2022 | 70.00M |
| March 31, 2022 | 61.00M |
| December 31, 2021 | 50.59M |
| September 30, 2021 | 71.25M |
| June 30, 2021 | 68.77M |
| March 31, 2021 | 66.39M |
| December 31, 2020 | 48.36M |
| September 30, 2020 | 51.80M |
| Date | Value |
|---|---|
| June 30, 2020 | 35.69M |
| March 31, 2020 | 23.14M |
| December 31, 2019 | 20.69M |
| September 30, 2019 | 17.24M |
| June 30, 2019 | 25.00M |
| March 31, 2019 | 15.55M |
| December 31, 2018 | 11.44M |
| September 30, 2018 | 12.86M |
| June 30, 2018 | 13.70M |
| March 31, 2018 | 11.65M |
| December 31, 2017 | 12.15M |
| September 30, 2017 | 21.44M |
| June 30, 2017 | 7.834M |
| March 31, 2017 | 5.804M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
17.24M
Minimum
Sep 2019
93.00M
Maximum
Dec 2023
58.26M
Average
66.39M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| Gilead Sciences Inc | 3.95B |
| Catalyst Pharmaceuticals Inc | 1.972M |
| Integra Lifesciences Holdings Corp | 24.28M |
| Palatin Technologies Inc | 5.554M |
| Petros Pharmaceuticals Inc | 0.8343M |